DK0812209T3 - Cochleatleveringsvehikel til biologisk relevante molekyler - Google Patents

Cochleatleveringsvehikel til biologisk relevante molekyler

Info

Publication number
DK0812209T3
DK0812209T3 DK96906334T DK96906334T DK0812209T3 DK 0812209 T3 DK0812209 T3 DK 0812209T3 DK 96906334 T DK96906334 T DK 96906334T DK 96906334 T DK96906334 T DK 96906334T DK 0812209 T3 DK0812209 T3 DK 0812209T3
Authority
DK
Denmark
Prior art keywords
biologically relevant
cochlate
delivery vehicle
relevant molecules
component
Prior art date
Application number
DK96906334T
Other languages
Danish (da)
English (en)
Inventor
Raphael James Mannino
Susan Gould-Fogerite
Original Assignee
Univ New Jersey Med
Albany Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Jersey Med, Albany Medical College filed Critical Univ New Jersey Med
Application granted granted Critical
Publication of DK0812209T3 publication Critical patent/DK0812209T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18834—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK96906334T 1995-02-22 1996-02-22 Cochleatleveringsvehikel til biologisk relevante molekyler DK0812209T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/394,170 US5840707A (en) 1993-10-04 1995-02-22 Stabilizing and delivery means of biological molecules
PCT/US1996/001704 WO1996025942A1 (fr) 1995-02-22 1996-02-22 Phospholipides cochleaires utilises dans l'administration de medicaments

Publications (1)

Publication Number Publication Date
DK0812209T3 true DK0812209T3 (da) 2004-09-13

Family

ID=23557861

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96906334T DK0812209T3 (da) 1995-02-22 1996-02-22 Cochleatleveringsvehikel til biologisk relevante molekyler

Country Status (11)

Country Link
US (1) US5840707A (fr)
EP (1) EP0812209B1 (fr)
JP (2) JP4535211B2 (fr)
AT (1) ATE265859T1 (fr)
AU (1) AU4974896A (fr)
CA (1) CA2212382C (fr)
DE (1) DE69632395T2 (fr)
DK (1) DK0812209T3 (fr)
ES (1) ES2220973T3 (fr)
PT (1) PT812209E (fr)
WO (1) WO1996025942A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018840A2 (fr) * 1995-11-22 1997-05-29 University Of Washington Liberation d'agents therapeutiques au moyen de composes auto-assembles pour former des microstructures a rapport axial eleve_
US6180114B1 (en) 1996-11-21 2001-01-30 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6340591B1 (en) 1998-12-14 2002-01-22 University Of Maryland Integrative protein-DNA cochleate formulations and methods for transforming cells
AU2007200813B2 (en) * 1999-01-22 2010-06-03 Biodelivery Sicencies, Inc. Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
US6153217A (en) * 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6274555B1 (en) 2000-05-15 2001-08-14 Lisa A. Berdami Composition and method for topical animal medication
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
CA2504329C (fr) 2002-11-01 2013-08-20 Biodelivery Sciences International, Inc. Vehicules pour administration de geodats
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20050008686A1 (en) * 2003-01-15 2005-01-13 Mannino Raphael J. Cochleate preparations of fragile nutrients
EP1596828B1 (fr) 2003-02-14 2011-12-28 Children's Hospital & Research Center at Oakland Vehicule d'administration de medicament lipophile et methodes d'utilisation correspondantes
US20050013854A1 (en) * 2003-04-09 2005-01-20 Mannino Raphael J. Novel encochleation methods, cochleates and methods of use
EP1631669A2 (fr) 2003-04-09 2006-03-08 Biodelivery Sciences International, Inc. Compositions contenant des structures cochleaires, dirigees contre l'expression de proteines
WO2005039534A1 (fr) * 2003-10-01 2005-05-06 Children's Hospital & Research Center At Oakland Vehicule d'administration de medicament lipophile et methodes d'utilisation de ce vehicule
EP1737427A2 (fr) * 2004-04-09 2007-01-03 Biodelivery Sciences International, Inc. Compositions nucleotide-cochleate et procedes d'utilisation
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
WO2008012629A2 (fr) 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Protéines de fusion d'extendine
WO2008024389A2 (fr) * 2006-08-23 2008-02-28 Biodelivery Sciences International, Inc. Compositions nucléotide-cochléate amphiphiles et procédés d'utilisation de celles-ci
US20080220028A1 (en) 2006-12-15 2008-09-11 National Research Council Of Canada Archaeal polar lipid aggregates for administration to animals
CA2678587A1 (fr) * 2007-02-28 2008-09-04 Paringenix, Inc. Heparines o-desulfatees pour traiter les exacerbations aigues de la bronchopneumopathie chronique obstructive
US20090036405A1 (en) * 2007-07-23 2009-02-05 University Of Utah Method for blocking ligation of the receptor for advanced glycation end-products (rage)
WO2009158678A1 (fr) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Véhicule d'administration d'acide nucléique lipophile et ses procédés d'utilisation
WO2011016043A2 (fr) 2009-08-06 2011-02-10 Technion Research & Development Foundation Ltd. Libération de médicament antibiotique et potentialisation
WO2012151517A1 (fr) 2011-05-05 2012-11-08 Coordinated Program Development, Llc Compositions de cochléate et leurs procédés de fabrication et d'utilisation
CN108498532B (zh) 2012-05-09 2021-07-23 坎泰克斯制药股份有限公司 骨髓抑制的治疗
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
KR101989789B1 (ko) 2017-11-30 2019-06-18 (주) 에이치엔에이파마켐 포스파티딜세린/음이온계면활성제/염화칼슘을 이용한 코킬레이트
EP4277654A1 (fr) 2021-01-18 2023-11-22 Conserv Bioscience Limited Compositions immunogènes de coronavirus, méthodes et utilisations de celles-ci
WO2024039733A1 (fr) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Procédés de régulation de la taille de particules de nanocristaux lipidiques et nanocristaux lipidiques produits par de tels procédés
WO2024039729A1 (fr) 2022-08-16 2024-02-22 Matinas Biopharma Nanotechnologies, Inc. Agent antifongique encapsulé dans un nanocristal lipidique pour le traitement de la mucormycose

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2249552A1 (de) * 1971-10-12 1973-05-30 Inchema S A Verfahren zur inkapsulation von insbesondere wasserloeslichen verbindungen
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles

Also Published As

Publication number Publication date
ES2220973T3 (es) 2004-12-16
WO1996025942A1 (fr) 1996-08-29
JPH11500443A (ja) 1999-01-12
ATE265859T1 (de) 2004-05-15
DE69632395T2 (de) 2005-05-04
AU4974896A (en) 1996-09-11
EP0812209A1 (fr) 1997-12-17
PT812209E (pt) 2004-09-30
JP2007197465A (ja) 2007-08-09
US5840707A (en) 1998-11-24
DE69632395D1 (de) 2004-06-09
EP0812209A4 (fr) 1999-11-03
EP0812209B1 (fr) 2004-05-06
CA2212382C (fr) 2009-04-28
JP4535211B2 (ja) 2010-09-01
CA2212382A1 (fr) 1996-08-29

Similar Documents

Publication Publication Date Title
DK0812209T3 (da) Cochleatleveringsvehikel til biologisk relevante molekyler
DE69114649D1 (de) In-line Gas/Flüssigkeitsdispersion.
CA2271244A1 (fr) Administration intracellulaire, assistee par pression, de molecules ou microparticules
MY107276A (en) Method and formulation employing type ii endoglycosidase
DK0457849T3 (da) Klæbemiddel til elektrotransport
BG101892A (en) Sugar-modified cytostatics
CA2246754A1 (fr) Vecteurs d'apport de structures cochleaires
DE69008080D1 (de) Verdampfungsvorrichtung für flüssigen Brennstoff.
ES2174768T1 (es) Genes de corynebacterium glutamicum que codifican proteinas del sistema fosfoenolpiruvato: azucar fosfotransferasa.
UA22113C2 (uk) Радіальhий підшипhик
ITTV930005A0 (it) Struttura di dispositivo di frenatura, particolarmente per pattini conruote in linea
AU7914600A (en) The use of baclofen in the treatment of alcohol withdrawal syndrome and to promote alcohol abstinence in alcoholics
IT1293978B1 (it) Vasca di fermentazione, particolarmente per la vinificazione in rosso.
ITTV950058A0 (it) Struttura di dispositivo frenante, particolarmente per pattini con ruote in linea
ITTV910115A1 (it) Dispositivo di frenatura, particolarmente per pattini con ruote in linea
ITMI940675A0 (it) Dispositivo per il disassamento di ruote, particolarmente per pattini con ruote in linea
IT1275476B (it) Dispositivo per il disassamento di ruote,particolarmente per pattini con ruote in linea
BR9507156A (pt) Enzimas codificadoras de dna da via glicolítica para uso em levedura para produção de álcool
ITBZ930004V0 (it) Disposizione di tassello,in particolare per il fissaggio di guarnitu- re per mobili.
IT9048012A0 (it) Cassettino porta-oggeti, in particolare per autoveicoli.
ES1004636U (es) Dispositivo de separacion transversal para estanterias lineales, gondolas y colocaciones lineales del mismo tipo.
SE9600759L (sv) Möbelsystem
DE60127389D1 (de) Pharmazeutische träger zusammensetzung für produkte auf basis von papain
ES1012210Y (es) Perfeccionamientos en las bombas de alimentacion de gasolina.
IT1267882B1 (it) Uso alternativo della molecola di o-(b-idrossietil)-rutosidea.